NOVELIXHealthcare Research, Analytics & Technology
NOVELIX PHARMACEUTICALS LIMITE — Cash Flow Statement
₹55.78
-3.48%
NOVELIX PHARMACEUTICALS LIMITE Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -13.69 Cr | -0.34 Cr | -2.41 Cr | -1.27 Cr | — |
| Issuance Of Capital Stock | 11.31 Cr | — | — | 0.00 | 0.00 |
| Capital Expenditure | -0.11 Cr | — | -43790.00 | -1.86 Cr | -0.03 Cr |
| End Cash Position | 0.68 Cr | 0.12 Cr | 0.27 Cr | 2.60 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -0.10 Cr | 2000.00 | — | -1000.00 | 1000.00 |
| Beginning Cash Position | 0.12 Cr | 0.27 Cr | 2.60 Cr | 1.74 Cr | — |
| Changes In Cash | 0.66 Cr | -0.16 Cr | -2.33 Cr | 0.87 Cr | — |
| Financing Cash Flow | 11.31 Cr | 0.00 | — | 0.00 | -0.77 Cr |
| Net Common Stock Issuance | 11.31 Cr | — | — | 0.00 | 0.00 |
| Common Stock Issuance | 11.31 Cr | — | — | 0.00 | 0.00 |
| Investing Cash Flow | 2.93 Cr | 0.19 Cr | 0.08 Cr | 0.28 Cr | — |
| Interest Received Cfi | 0.02 Cr | 0.31 Cr | 0.52 Cr | 0.55 Cr | — |
| Net Investment Purchase And Sale | 3.02 Cr | 0.17 Cr | 2.28 Cr | 1.56 Cr | — |
| Sale Of Investment | 3.02 Cr | 0.31 Cr | 2.28 Cr | 1.56 Cr | — |
| Net PPE Purchase And Sale | -0.11 Cr | 0.02 Cr | -43790.00 | -1.83 Cr | — |
| Purchase Of PPE | -0.11 Cr | — | -43790.00 | -1.86 Cr | -0.03 Cr |
| Operating Cash Flow | -13.58 Cr | -0.34 Cr | -2.41 Cr | 0.59 Cr | — |
| Change In Working Capital | -13.83 Cr | -0.10 Cr | -1.89 Cr | 1.12 Cr | — |
| Change In Payable | 8.41 Cr | -0.05 Cr | 0.05 Cr | -0.02 Cr | — |
| Change In Inventory | 0.35 Cr | -0.38 Cr | -0.29 Cr | -0.28 Cr | — |
| Change In Receivables | -22.59 Cr | 0.33 Cr | -1.65 Cr | 1.42 Cr | — |
| Other Non Cash Items | -0.02 Cr | -0.31 Cr | -0.27 Cr | -0.30 Cr | — |
| Depreciation And Amortization | 0.04 Cr | 0.04 Cr | 0.06 Cr | 0.07 Cr | — |
| Depreciation | 0.04 Cr | 0.04 Cr | 0.06 Cr | 0.07 Cr | — |
| Net Income From Continuing Operations | 0.12 Cr | 0.02 Cr | -0.06 Cr | -1.57 Cr | — |
| Net Other Investing Changes | — | -1000.00 | -2.72 Cr | -24000.00 | 1000.00 |
| Purchase Of Investment | — | -0.14 Cr | — | -0.05 Cr | -0.28 Cr |
| Sale Of PPE | — | 0.02 Cr | — | 0.03 Cr | 0.00 |
| Amortization Cash Flow | — | 0.00 | 0.00 | 0.02 Cr | — |
| Gain Loss On Investment Securities | — | -0.07 Cr | -0.24 Cr | 1.49 Cr | -96000.00 |
| Gain Loss On Sale Of PPE | — | -0.04 Cr | — | 0.02 Cr | — |
| Net Issuance Payments Of Debt | — | — | — | 0.00 | -0.77 Cr |
| Net Long Term Debt Issuance | — | — | — | 0.00 | -0.77 Cr |
| Net Intangibles Purchase And Sale | — | — | — | 0.00 | — |
| Purchase Of Intangibles | — | — | — | 0.00 | — |
| Taxes Refund Paid | — | — | — | 0.00 | -0.03 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on NOVELIX PHARMACEUTICALS LIMITE
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.